PROGRAM

Chairmen: JB Vermorken, R. Ozols, A. Poveda

Valencia 26th February 1999

09.00-10.00 GENETICS

- Molecular approaches to epithelial ovarian cancer: potential implications for therapy.
  R.C. Bast (Houston, USA)

10.00-11.30 SURGERY

- Surgical staging, surgical guidelines and the importance of lymphadenectomy vs lymph node sampling in ovarian cancer.
  J.B. Trimbos (Leiden, The Netherlands)

- Surgical vs chemical upfront debulking in advanced ovarian cancer.
  S. Pecorelli (Brescia, Italy)

- The impact of a specialist training for surgery in ovarian cancer
  E. Junor (Glasgow, Scotland)

11.30-12.00 COFFE BREAK

12.00-13.30 CHEMOTHERAPY

State of the art lectures with respect to:

- Intravenous chemotherapy
  S.B. Kaye (Glasgow, Scotland)

- Intraperitoneal chemotherapy
  J.B. Vermorken (Antwerp, Belgium)

- Consolidation therapies
  R. Ozols (Philadelphia, USA)

14.00 LUNCH

15.30-17.50 FUTURE DIRECTIONS

- New cytotoxics and noncytotoxics
  E.A. Eisenhauer (Kingston, Canada)

- The use of monoclonal antibodies intraperitoneally
  A.A. Epenetos (London, UK)

- Strategies for resistance modulation
  E.G.E. de Vries (Groningen, The Netherlands)

- Possible roles for high-dose chemotherapy with PBSCT
  J.A. Ledermann (London, UK)

17.50-18.00 Remarks and conclusions

A. Poveda (Valencia, Spain)

Sponsored by ESMO and SEOM